Biochemistry & Pharmacology: Open Access

Biochemistry & Pharmacology: Open Access
Open Access

ISSN: 2167-0501

+44-77-2385-9429

Research Article - (2015) Volume 4, Issue 2

Low Serum Zinc and Increased Acid Phosphatase Activity in Type 2 Diabetes Mellitus with Periodontitis Subjects

Pushparani DS*
Department of Biochemistry, SRM Dental College, SRM University, Ramapuram, Chennai-600089, Tamil Nadu, India
*Corresponding Author: Pushparani DS, Department of Biochemistry, SRM Dental College, SRM University, Ramapuram, Chennai-600089, Tamil Nadu, India, Tel: +91-9962476540 Email:

Abstract

Micronutrient zinc plays a major role in influencing the periodontal conditions in Type 2 diabetes mellitus (T2DM) subjects. In the developed countries nearly 40% of the people are zinc deficient among the T2DM. Now it is estimated that nearly 2 billion subjects in the developing world may be zinc deficient. The periodontal diseases are highly prevalent and can affect up to 90% of the world wide population. Many chronic diseases have been associated with periodontal disease which results in adverse pregnancy outcomes, cardiovascular disease, stroke, pulmonary disease, and diabetes, but the causal relations have not been established. Zinc in human play an important role in cell mediated immunity and was also an antioxidant and anti-inflammatory agent. Zinc helps in the stabilization of lysosomal membranes. The increased acid phosphatase activity might be a result of destructive processes in alveolar bone in advanced stages of periodontal disease. In light of the available data, the study aimed to show how low serum zinc and increased level of lysosomal enzyme, acid phosphatase affect the subjects of Type 2 diabetes mellitus with periodontitis.

<

Keywords: Acid phosphatase; Inflammation; Periodontitis; Type 2 diabetes mellitus; Zinc

Introduction

Type 2 diabetes mellitus (T2DM) is one of the most challenging health concerns of the 21st century. It is a chronic disease reaching epidemic levels in both developed and developing countries. According to International Diabetes Federation (IDF), Diabetes Atlas, sixth edition, the prevalence of T2DM is increasing at an alarming rate, affecting 382 million people worldwide in 2013 and this would rise to 592 million in 2035 [1]. The West Pacific Region is home to one quarter of the world’s population, and China now has the largest patient population with diabetes as well as Pacific Islands countries with the highest prevalence rates. The incidence of periodontitis is rapidly increasing worldwide and is still a significant problem for many patients with T2DM [2]. The expression of a range of immune mediators, such as C-reactive protein (CRP) and the inflammatory cytokines interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF)-α, are often reported in T2DM [3]. The possible for the dietary components to modulate inflammatory processes are found to be a new approach in the management of T2DM [4].

Periodontitis is considered as one of the main, oral health problems encountered in patients with diabetes mellitus. Periodontitis affects approximately 50% of adults and over 60% of over 65 year olds, with severe periodontitis impacting 10–15% of populations [5,6]. Periodontal disease is a microbially initiated chronic inflammatory disease, in which dysregulated immune-inflammatory processes are responsible for the majority of host tissue destruction, and ultimately tooth loss [7]. Periodontal disease is associated with increased incident diabetes risk, poor glycemic control, and diabetic complications, probably due to the higher levels of systemic proinflammatory mediators that exacerbate insulin resistance [8,9].

Polymorphonuclear leukocytes (PMNLs) are the primary defence cells of the periodontium. In uncontrolled diabetes, reduced PMNL function and defective chemotaxis can give rise to impaired host defences and development of disease [10]. Plenty of microbial antigens stimulate both humoral antibody-mediated and cell mediated immune responses are usually safety, but a continual microbial task in the use of the fore mentioned risks results in the malfunction of both soft and hard tissues, mediated by cytokine and prostanoid flows. Both the host and bacteria in the periodontal biofilm liberate proteolytic enzymes that damage tissue [11]. They release chemotactic factors that hire polymorphonuclear leucocytes into the tissues; if continual, these cells discharge various enzymes that break down tissues. Once a periodontal pocket forms and becomes packed with bacteria, the situation becomes mostly permanent and produce pro-inflammatory cytokines and mediators [12,13]. Peripheral blood monocytes from diabetic subjects produce elevated levels of tumor necrosis factoralpha (TNF-α) in response to antigens from Porphyromonas gingivalis compared to monocytes from non-diabetic control subjects [14]. During phagocytosis, the granular (lysosomal) enzymes are released from polymorphonuclear cells into the extracellular medium.

Gingival epithelial cells function as an innate host defense system to prevent intrusion by periodontal bacteria. However, persistent contact of sub-gingival bacterial biofilm with gingival crevices induces bacterial penetration into periodontal tissues. Immunofluorescence and immunehistochemical techniques have revealed the existence of Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia, and Actinomycesnaes lundii in gingival tissues [15]. In addition, intra cellular localization of several periodontal bacteria, including P. gingivalis, A. actinomycetemcomitans,Tannerella forsythia, and Treponemadenticola has been identified.

Acid phosphatases (EC 3.1.3.2) are generally classified as nonspecific enzymes and often occur in multiple molecular forms [16]. It is one among the hydrolytic enzymes associated with lysosomes of cells from a variety of tissues. They differ in molecular size and cellular localisation, as well as in substrate specificity and susceptibility to inhibitors. There is also a particular class of ACPs that require metal ions for activity [17]. The Zn2+ dependent ACP has been detected in several animal tissues and species [18]; two main molecular forms, differing in tissue distribution, have been found. Brain, heart, skeletal muscle, erythrocytes, lung, spleen, and stomach contain a 62 kDa molecular form of the Zn2+ dependent ACP, whereas liver contains a higher molecular weight form of the enzyme. The small intestine and kidney contain both high and low molecular weight forms [19].

Zinc is required by all cell types, playing crucial catalytic, structural and regulatory roles, by binding to a zinc proteome estimated in humans to contain approximately 3000 members [20]. Crystallographic studies have demonstrated the presence of zinc in the crystal of insulin. There are several reasons to suspect, that abnormal zinc metabolism could play a role in the pathogenesis of diabetes mellitus and some of its complications. Several human studies confirmed that diabetes had an effect on disrupting Zn homeostasis. A defect in Zn homeostasis may affect the signal transduction response to insulin and by reducing the production of cytokines, which lead to beta-cell death during the inflammatory process in the pancreas [21]. Under normal conditions Zn is found throughout the pancreas, where it forms an integral component of the insulin crystalline structure [22], serving to stabilize the insulin granule by rendering it less soluble [23].

Zinc interacts with general metabolism of protein, carbohydrate and lipid, as well as on taste, smell, appetite regulation and food consumption. This micronutrient participates both in the synthesis and actions of these hormones, which are intimately linked to bone metabolism. In vitro studies have shown that Zn stimulates osteoblastic bone formation [24]. The basic mechanisms of action of this trace element are intimately linked to the structure and action of countless enzymes involved in many different metabolic processes. In this respect, when Zn specifically acts on cartilage growth it is involved in multiple enzymatic reactions which make this a multi factorial event. Zn could decrease the extent of oxidative damage by decreasing free radical production at the ligand-binding site; and through its role in the Cu–Zn superoxide dismutase enzyme [25,26]. In animals, Zn supplementation lowers elevated blood glucose in genetically obese mice [27] and reduces the extent of lipid peroxidation and atherosclerotic plaques in rabbits on a high-cholesterol diet even though these animals are not Zn deficient [28]. The interaction between glycemic markers and serum zinc levels in humans is unclear. Therefore, with the available data, the present study aimed to study the relationship between serum zinc and acid phosphatase level in type 2 diabetes mellitus with periodontitis.

Materials and Methods

Study participants

The study consisted of a total of 600 subjects in the age group of 25 to 56 years. The subjects were divided into four groups, consisting of 150 participants in each group as:

Group I: Control healthy subjects

Group II: T2DM without periodontitis

Group III: T2DM with periodontitis

Group IV: Non-DM with periodontitis

Group I subjects were selected from a generalised population. Group II subjects for the studies were enrolled from the SRM Speciality Hospital, India and group III and group IV subjects were selected from the outpatients attending the Department of Periodontology and Oral Implantology, SRM Dental College, India. The study plan was approved by the Institutional Ethical Committee of Medical and Health Sciences, SRM University, India and an informed written consent was obtained from all the participants.

Clinical assessments

Relevant clinical history and physical examination were recorded for all the subjects. Six milliliters of fasting blood sample was withdrawn from ante-cubital vein under aseptic precautions and collected into the vials for assessment of various parameters. All subjects were submitted blood collection, number of teeth present and missing, pathological migration, and probing depth (PPD) and clinical attachment level (CAL) evaluation.

Patients with diabetes mellitus were under diabetic diet and did not take nutritional supplements and any drugs that are known to interfere with the serum levels of studied metals during the period of study. The healthy controls were not on any kind of prescribed medication or dietary restrictions.

Inclusion and exclusion criteria

All periodontitis individuals included under the category of periodontitis should have more than 30% of the sites with Clinical attachment level (CAL) ≥ 3mm and pocket depth (PD) ≥ 5 mm, at least 2 teeth in each quadrant with the condition of 20 teeth in all the subjects. Diabetic subjects should have T2DM, diagnosed by a physician by means of the oral glucose tolerance test, for at least the past 5 years.

Type 2 diabetic patients having vascular complications as diabetic nephropathy, neuropathy and retinopathy were excluded from the study. Smokers, alcoholics, drug abused, patients who had periodontal therapy six months prior to the study, patients under antibiotics and having systemic disease other than diabetics, taking hormone drugs, lipid lowering drugs, hypotensive diuretics, oral contraceptives, and pregnant women, were excluded from the study.

Basic measurements and assays

BMI was calculated based on measures of body weight and height as weight in kilograms divided by height in meters squared. The systolic and diastolic blood pressure was determined as the mean of two measurements. Blood samples were collected after an overnight fast for each subject. Serum was obtained by centrifuging the blood at 1500 rpm for 10 minutes. HbA1c was analyzed by the high-performance liquid chromatography method (Biosystems S.A, Costa Brava, Spain) and results are expressed in percentage, with a reference value of 5 to 7%. Serum glucose was measured by the glucose oxidase-peroxidase (GOD-POD) method, using the reagent kit purchased from Merck Specialities Private Limited, India.

Serum zinc was estimated, using the Nitro-PAPS (pyridylazo-Npropyl- N-sulfopropylamino-Phenol) method, and the values expressed in μg/dl. Acid phosphatase (ACP) was analysed by the technique described by Gutman and Gutman [29], using di sodium phenyl phosphate as the substrate. The incubations were performed at 37ºC for 1 hour, and the reaction was stopped by adding 10% trichloroacetic acid. After removal of the precipitate, the concentration of ACP was determined by the differences in extinction at 620 nm against the reagent blank in a spectrophotometer. This difference in extinction was used as a measure of enzyme activity. The enzyme activity was expressed as micromoles of substrate hydrolysed/ min/ L.

Statistical analysis

Data were presented as mean ± SD (standard deviation). An unpaired Student’s t test and Newman-Keuls multiple comparison test were used to evaluate the differences between groups. Correlations between various variables are done using Pearson’s correlation equations. The statistical significance was taken as p<0.05. All statistical analysis was performed, using the statistical software package, Winks SDA 7.0.5 (Windows Kwik Stat).

Results

The demographic characteristics within group I (healthy controls), group II (T2DM without periodontitis), group III (T2DM with periodontitis) and group IV (Non-DM with periodontitis) are shown in Table 1.There were no statistical differences in the mean of the systolic blood pressure, and diastolic blood pressure among the four groups. The mean (± SD) percentages of HbA1c levels was found to be 7.74 ± 1.31 in group II and 8.38 ± 1.17 in group III and are statistically significant when compared to control. However, T2DM patients with periodontitis had significantly higher HbA1c than T2DM patients without periodontitis and there was no significant difference between the Group IV and Group I (control) subjects.

Parameters Control Group I T2DM without    periodontitisGroup II T2DM with periodontitisGroup III Non-DM withperiodontitisGroup IV
No of subjects 150 150 150 150
Gender (M/F) 80/70 78/72 77/73 75/75
Age,   years 35.46 ±  10.74 46.26 ± 10.02*** 44.42 ± 10.37*** 41.66 ± 10.45***
Duration of diabetes, years - 8.39 ±  5.35 8.70 ±  4.82 -
HbA1c % 5.20 ± 0.51 7.74 ± 1.31*** 8.38 ± 1.17*** 5.14 ± 0.56 NS
BMI, kg/m2 22.72 ± 1.5 23.32 ± 1.49** 24.07 ± 1.51** 23.93 ± 1.12**
Systolic blood pressure(mm Hg) 119.5 ± 4.65 126.4 ± 5.70NS 128.8 ± 5.09NS 126.7 ± 8.39NS
Diastolic blood pressure(mm Hg) 72.93 ± 2.10 75.14 ± 1.78NS 79.05 ± 3.03NS 76.47 ± 4.52NS

Values are expressed as Mean ± SD; except for gender (Male, M / Female, F). Glycosylated hemoglobin, HbA1c; Body mass index, BMI. Differences were considered significant at ***p<0.0001; **p<0.001for parameters of group II, III, IV vs group I and NS, non-significant

Table 1: Demographic characteristics of the study population within the four groups

The clinical parameters descriptive statistics are shown in Table 2. The mean FBG level was significantly elevated in the group II and group III subjects, when compared to group I and group IV. As expected the mean levels of periodontal probing depth (PPD) and clinical attachment level (CAL), were significantly greater than 4 mm in T2DM with periodontitis and in Non-DM with periodontitis, when compared to healthy subjects.

Parameters Control Group I T2DM without    periodontitis Group II T2DM with periodontitis Group III Non-DM withperiodontitisGroup IV
No of subjects 150 150 150 150
Gender (M/F) 80/70 78/72 77/73 75/75
FBG, mg/dl 95.28 ± 12.51 183.7 ± 57.16*** 176.7 ± 59.12*** 96.88 ± 12.67NS
PPD, mm 1.45  ± 0.13 1.42 ± 0.17NS 4.61± 0.51***   4.67  ± 0.46***
CAL, mm 0.708  ± 0.27 0.64 ± 0.49NS 4.91± 0.37*** 4.62  ± 0.58***

Values are expressed as Mean ± SD; except for gender (Male, M / Female, F). Fasting blood glucose, FBG; Periodontal probing depth, PPD; Clinical attachment level, CAL. Differences were considered significant at ***p<0.0001; **p<0.001; *p<0.05 for parameters of group II, III, IV vs group I and NS, non-significant.

Table 2: Clinical characteristics of the study population.

The serum concentration of zinc in groups I, II, III and IV is shown in Figure 1. According to the Newman-Keuls Multiple Comparison test, the means levels of the serum zinc of group III was lesser than the means of all other groups. At p<0.05, the means of group III was significantly different when compared to other groups. Our data show that T2DM with periodontitis (106.8 ± 31.83) individuals have lower zinc than those without this disease. The serum zinc level in T2DM without periodontitis (157.2 ± 45.8, group II) and Non-DM with periodontitis (135.7 ± 51.39, group IV) which are found to be significantly higher when compared to control (113.4 ± 12.65, group I).

biochemistry-pharmacology-periodontitis

Figure 1: Serum zinc level in the healthy control (group I), T2DM without periodontitis (group II), T2DM with periodontitis (group III) andNon-DM with periodontitis (group IV). The box represents the mean, mean ± SD and the range. Differences were considered significant at *** p<0.0001; ** p<0.001 when compared to control.

The expression of Acid phosphatase was found to be ten times increased in group III whereas the levels were found to be elevated three times in group II, and four times in the group IV subjects (Figure 2). We found a significant positive correlation between serum zinc and acid phosphatase among the group II (T2DM without periodontitis),and group IV (Non-diabetes with periodontitis) but no correlation with group I and group III (T2DM with periodontitis) (Figure 3a- 3d). In T2DM without periodontitis (group II), ACP showed positive correlation with FBG. Among the T2DM with periodontitis (groupIII), ACP showed positive correlation with PPD and it showed negative correlation with CAL, and zinc correlated positively with fasting blood glucose (Table 3).

biochemistry-pharmacology-Serum-Acid

Figure 2: Serum Acid phosphatase (micromoles/min/L) in the healthy control (group I), T2DM without Serum-Acid (group II), T2DM with Serum-Acid (group III) and Non-DM with Serum-Acid (group IV). Differences were considered significant at ***p<0.0001 when compared to control.

biochemistry-pharmacology-Zinc-Acid

Figure 3a: 3a: Pearson’s correlation plots showing the relationship between serum Zinc and Acid phosphatase in Control healthy individuals.

biochemistry-pharmacology-serum-Zinc

Figure 3b: Pearson’s correlation plots showing the relationship between serum Zinc and Acid phosphatase in T2DM without periodontitis.

biochemistry-pharmacology-phosphatase

Figure 3c: Pearson’s correlation plots showing the relationship between serum Zinc and Acid phosphatase in T2DM with periodontitis.

biochemistry-pharmacology-Acid-phosphatase

Figure 3d: Pearson’s correlation plots showing the relationship between serum Zinc and Acid Acid-phosphatase in Non-DM with periodontitis.

Parameters Control Group I T2DM without    periodontitis Group II T2DM with periodontitis Group III Non-DM withperiodontitis Group IV
Zinc r p r p r p r P
               
   HbA1c 0.024 0.809 0.000 0.100 0.024 0.813 0.0816 0.420
      FBG  −0.107 0.390 0.006 0.446 0.216 0.002* 0.133 0.333
    PPD 0.266   0.437 0. 030    0.766 -0.123 0.445 -0.112   0.266
   CAL −0.033 0.331 0.039 0.693 0.065 0.257 0.125 0.214
Acid phosphatase                
   HbA1c -0.139 0.167 -0.045 0.655 0.009 0.924 -0.129 0.199
   FBG   -0.141 0.160 0.170 0.049* -0.023 0.813 0.039 0.696
  PPD -0.008 0.936 -0.003 0.976 0.193 0.054 -0.028 0.777
   CAL -0.038 0.702 0.032 0.746 -0.327 0.000* -0.062 0.537

Pearson coefficient ratio, r; Glycosylated hemoglobin, HbA1c; Fasting blood glucose, FBG; Periodontal probing depth, PPD; Clinical attachment level, CAL, *significant p value.

Table 3: Pearson correlation between Zinc and Acid phosphatase with other independent variables in the 4 groups.

Discussion

Antioxidants play a role as defenders against occurred damages by metal-mediated free radicals. Zinc acts as an antioxidant for the decrease of oxidative stress [30]. Usually the serum Zn concentration is used to determine the Zn status, but the serum Zn concentration is not only decreased in real Zn deficiency, but also in stress [31]. During stress, serum Zn is redistributed from the serum into the liver. The protective effects of zinc against increased rates of lipid peroxidation could be due to its capability to combine and strengthen cellular membranes against lipid peroxidation and disintegration. Another probable protective mechanism of metallothionein is its ability to release Zn for binding at sites on membrane surfaces, displacing adventitious iron thereby inhibiting lipid peroxidation. A substitute protective mechanism of Zn may be its capacity to induce metallothionein synthesis. The high sulfhydryl content enables metallothionein to efficiently scavenge oxyradicals [32]. Furthermore, the suggested outcome of Zn in causing the SH-rich metallothionein synthesis may preserve the SH-residue in many functional proteins. Therefore, Zn may protect the structural and functional integrity of the SH dependent enzymes including those regulating glucose metabolism.

Acid phosphatase (ACP) activity is widespread throughout nature. It has been widely investigated amongst the lysosomal enzymes, and has often been used as a lysosomal marker. Enzyme reactions are inhibited by metals which may form a complex with the substrate, combine with the protein-active groups of the enzymes, or react with the enzyme-substrate complex. This ACP is transported to lysosomes as an integral protein with the lysosomal targeting signal contained in the cytoplasmic tail [33]. Metals play a central role in life processes of living organisms. Essential metals are catalysts in biochemical reactions function as stabilizers of protein structures and serve in maintaining an osmotic balance. High concentrations of most metals essential and non-essential are toxic for living cells. Zinc can act as co-factors for several enzymes. At pH 5.5, the Zn ion is an essential activator, since the enzyme shows no activity in the absence of this ion. Metal treatment may affect cell and/or mitochondrial membrane permeability, lysosome membrane stability, protein unfolding and/or precipitation, enzyme inhibition, irreversible conformational changes and mutations in nucleic acids [34].

In our study, the ACP level was found to be increased significantly to about ten times (10.09 ± 2.46) among the T2DM with periodontitis (group III) when compared to control (1.18 ± 0.47). We also observed that the ACP level was increased in to about three times in group II (3.50 ± 1.27) and four times (4.38 ± 3.15) in group IV subjects. This finding is in agreement to the findings of Agoda and Glew [35] who found elevated activity of ACP in diabetes mellitus. When comparison was done between diabetes with and without periodontitis, a statistically significant increase was found in diabetes with periodontitis group. But the level of enzyme concentration is increased three times in group II and four times in group IV. This gives for the evidence that, the increased activity of this enzyme in diabetes with periodontitis may be as a result of decreased serum Zn in group III.

ACP was found to be elevated in diabetes mellitus. We found higher activity of acid phosphatase in T2DM with periodontitis [36] which would indicate that in these patients the activation process is not restricted to the enzymes capable of degrading mucopolysaccharides and gycloproteins and the levels of ACP correlate with measurements of disease severity or activity. Hydrolysis of a variety of orthophosphate esters as well as transphosphorylation reactions is catalyzed by enzymes from many sources. One of the possible explanations for this relation could be that the insufficient influx of glucose into cells owing to the lack of insulin led to the decreased synthesis of adenosine triphosphate (ATP).

The presence of acid phosphatase in serum arises from various sources, including erythrocytes, leukocytes, platelets, kidneys, spleen and liver, each of which contribute molecular variants (isoenzymes) of ACP that are specific to the organ or cells of origin. It was observed that zinc correlated positively with ACP among the group II and group IV subjects. The correlation between ACP activity and zinc concentration may reflect a common origin of these two substances, or binding of Zn by acid phosphatise [37]. Various studies have shown that ACP, which is an important marker of phagocytic activity in phagocytes (activated macrophages and neutrophils).

Results obtained in the present study indicate a close and complex relationship between lysosomal and antioxidant responses to metals. These elements in fact could exert their toxicity both through a direct and indirect pathway, the effects of which are not easy to distinguish. The direct effect of zinc could be related to the binding of these elements to the lysosomal membrane, to the increased loading of metal-binding proteins within the lysosomal compartment, as well as to the removal of antioxidant compounds (through oxidation or mixed complexes formation) and inhibition of antioxidant enzymes. Further, metals could have an indirect effect mediated by the formation of oxy radicals. These reactive species could enhance lysosomal damage by promoting the peroxidation of membranes and in the meantime would further reduce the antioxidant cellular defenses. In this respect, it could be speculated that lysosomal damage is at least in part dependent on the efficiency of antioxidant mechanisms. In fact, as more of these defenses are depleted, the more severe will be the indirect effects of zinc metal on lysosomal membranes.

ACP is among the enzymes associated with bone metabolism. It is present in neutrophils and considered a lysosomal marker. Desquamated epithelial cells, macrophages and several bacteria, including Actinobacillus, Capnocytophaga and Veillonella, also produce this enzyme. The increased activity might be a consequence of destructive processes in alveolar bone in advanced stages of development of periodontal disease [38]. The demise associated with tissue can cause a discharge of lysosomal enzymes, with a destruction of the nearby tissue. The extracellular ACP found in gingival fluid could represent an accumulation of lysosomal enzyme from the rapidly desquamating epithelial cells of the crevicular epithelium or from connective tissue cells. It may have a bacterial origin and for that reason they play a role in the formation of pathological pocket [39]. Among its isozymes circulating L-tartrate-resistant acid phosphatase has been shown to be a sensitive marker for evaluation of osteoclastic function. Bone histology and biochemical markers of bone formation and resorption in the diabetic animal models indicated a decreased osteoblast activity combined with normal or decreased osteoclast activity [40].

Human ACP is normally found at low concentrations. However, pronounced changes in their synthesis occur in particular diseases, where unusually high or low enzyme expression is seen as part of the patho-physiological process [41]. In our study, the result of ACP is highly increased in T2DM with periodontitis when compared to other groups. Different forms of ACP are found in different organs, and their serum levels are used as a diagnostic tool for many diseases. Therefore,decreased zinc and elevated level of ACP may be a contributing factor for the progression of T2DM with periodontitis. Pro- and antiinflammatory processes are crucial in the different phases of wound healing and their disturbances interfere with tissue homeostasis and wound healing.

Acknowledgements

The author would like to thank the Management, Dean and Vice-Principal of SRM Dental College, SRM University, Ramapuram, Chennai, for supporting and providing all the laboratory facilities to carry out the experimental work.

References

  1. Patterson C, Guariguata L, Dahlquist G, Soltész G, Ogle G, et al. (2014) Diabetes in the young - a global view and worldwide estimates of numbers of children with type 1 diabetes.  Diabetes Res Clin Pract 103: 161-175.
  2. Costanian C, Bennett K, Hwalla N, Assaad S, Sibai AM (2014) Prevalence, correlates and management of type 2 diabetes mellitus in Lebanon: findings from a national population-based study.  Diabetes Res Clin Pract 105: 408-415.
  3. Fernández-Real JM, Vendrell J, García I, Ricart W, Vallès M (2012) Structural damage in diabetic nephropathy is associated with TNF-Î ± system activity.  Acta Diabetol 49: 301-305.
  4. Gupta S, Gambhir JK, Kalra O, Gautam A, Shukla K, et al. (2013) Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population.  J Diabetes Complications 27: 548-552.
  5. Fox CH (1992) New considerations in the prevalence of periodontal disease.  Curr Opin Dent 2: 5-11.
  6. White D, Pitts N, Steele J, Sadler K, Chadwick B (2011) Diseases and related disorders - a report from the Adult Dental Health Survey 2009. London: NHS Information Centre for Health and Social Care.
  7. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ, et al. (2012) CDC Periodontal Disease Surveillance workgroup: James Beck (University of North Carolina, Prevalence of periodontitis in adults in the United States: 2009 and 2010.  J Dent Res 91: 914-920.
  8. Lalla E, Papapanou PN (2011) Diabetes mellitus and periodontitis: a tale of two common interrelated diseases.  Nat Rev Endocrinol 7: 738-748.
  9. Chang PC, Lim LP (2012) Interrelationships of periodontitis and diabetes: A review of the current literature. Journal of Dental Sciences 7: 272-282.
  10. Duarte PM, Napimoga MH, Fagnani EC, Santos VR, Bastos MF, et al. (2012) The expression of antioxidant enzymes in the gingivae of type 2 diabetics with chronic periodontitis.  Arch Oral Biol 57: 161-168.
  11. Kinane DF, Preshaw PM, Loos BG; Working Group 2 of Seventh European Workshop on Periodontology (2011) Host-response: understanding the cellular and molecular mechanisms of host-microbial interactions--consensus of the Seventh European Workshop on Periodontology.  J Clin Periodontol 38 Suppl 11: 44-48.
  12. Kim EK, Lee SG, Choi YH, Won KC, Moon JS, et al. (2013) Association between diabetes-related factors and clinical periodontal parameters in type-2 diabetes mellitus.  BMC Oral Health 13: 64.
  13. Salvi GE, Collins JG, Yalda B, Arnold RR, Lang NP, et al. (1997) Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases.  J Clin Periodontol 24: 8-16.
  14. Guzman S, Karima M, Wang HY, Van Dyke TE (2003) Association between interleukin-1 genotype and periodontal disease in a diabetic population.  J Periodontol 74: 1183-1190.
  15. Sardi JC, Duque C, Camargo GA, Hofling JF, Gonçalves RB (2011)  Periodontal conditions and prevalence of putative periodontopathogens and Candida spp. in insulin-dependent type 2 diabetic and non-diabetic patients with chronic periodontitis—A pilot study. Archives of oral biology 56: 1098-1105.
  16. Hayman AR, Cox TM (2003) Tartrate-resistant acid phosphatase knockout mice.  J Bone Miner Res 18: 1905-1907.
  17. Panara F, Angiolillo A, Fagotti A, Di Rosa I, Francesca S, et al. (1992) Acid phosphatases in mammalian tissues. Evidence for the existence of a 57 kDa Zn(2+)-dependent acid phosphatase form.  Int J Biochem 24: 1619-1623.
  18. Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function.  Calcif Tissue Int 34: 285-290.
  19. Togawa T, Takada M, Aizawa Y, Tsukimura T, Chiba Y, et al. (2014) Comparative study on mannose 6-phosphate residue contents of recombinant lysosomal enzymes. Molecular Genetics and Metabolism 111: 369–373.
  20. Plum LM, Rink L, Haase H (2010) The essential toxin: impact of zinc on human health.  Int J Environ Res Public Health 7: 1342-1365.
  21. Mocchegiani E, Giacconi R, Malavolta M (2008) Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes.  Trends Mol Med 14: 419-428.
  22. Pushparani DS, Anandan SN, Theagarayan P (2014) Serum zinc and magnesium concentrations in type 2 diabetes mellitus with periodontitis.  J Indian Soc Periodontol 18: 187-193.
  23. Roussel AM, Kerkeni A, Zouari N, Mahjoub S, Matheau JM, et al. (2003) Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus.  J Am Coll Nutr 22: 316-321.
  24. Yamaguchi M, Weitzmann MN (2011) Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation.  Mol Cell Biochem 355: 179-186.
  25. Maret W, Sandstead HH (2006) Zinc requirements and the risks and benefits of zinc supplementation.  J Trace Elem Med Biol 20: 3-18.
  26. Rungby J (2010) Zinc, zinc transporters and diabetes.  Diabetologia 53: 1549-1551.
  27. Capdor J, Foster M, Petocz P, Samman S (2013) Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans.  J Trace Elem Med Biol 27: 137-142.
  28. Foster M, Petocz P, Samman S (2013) Inflammation markers predict zinc transporter gene expression in women with type 2 diabetes mellitus.  J Nutr Biochem 24: 1655-1661.
  29. Gutman AB, Gutman EB (1938) An “Acid " Phosphatase Occurring In The Serum Of Patients With Metastasizing Carcinoma Of The Prostate Gland.  J Clin Invest 17: 473-478.
  30. Myers SA, Nield A, Myers M (2012) Zinc transporters, mechanisms of action and therapeutic utility: implications for type 2 diabetes mellitus.  J Nutr Metab 2012: 173712.
  31. Jagdish K, Mehul S, Nehal S (2010) Effect of Hesperidin on serum glucose, HbA1c and oxidative Stress in myocardial tissue in experimentally induced myocardial infarction in diabetic rats. Pharmacognosy Journal 2: 185-189.
  32. Lal M, Sudha K, Beena VS,Gayathri MR (2013) Influence of modified levels of plasma modified levels of plasma magnesium, Cu, Zn and Iron levels on thiols and protein status in diabetes mellitus and diabetic retinopathy. International Journal of Analytical Pharmaceutical and Biomedical Sciences 2: 67-72.
  33. Moustafa SA (2004) Zinc might protect oxidative changes in the retina and pancreas at the early stage of diabetic rats.  Toxicol Appl Pharmacol 201: 149-155.
  34. Bull H, Murray PG, Thomas D, Fraser AM, Nelson PN (2002) Acid phosphatases.  Mol Pathol 55: 65-72.
  35. Fujimoto S, Okano I, Tanaka Y, Sumida Y, Tsuda J, et al. (1996) Zinc-ion-dependent acid phosphatase exhibits magnesium-ion-dependent myo-inositol-1-phosphatase activity.  Biol Pharm Bull 19: 882-885.
  36. Kwapiszewski R, Kwapiszewska K, Kutter JP, Brzozka Z (2015) Three-layer poly(methyl methacrylate) microsystem for analysis of lysosomal enzymes for diagnostic purposes.  Anal Chim Acta 853: 702-709.
  37. Pushparani DS, Nirmala S (2013) Comparison of Acid phosphatase and ß D-Glucuronidase Enzyme Levels in Type 2 Diabetes Mellitus with and without Periodontitis. IJSER 4: 1164-1168.
  38. Yoshie H, Tai H, Kobayashi T, Oda-Gou E, Nomura Y, et al. (2007) Salivary enzyme levels after scaling and interleukin-1 genotypes in Japanese patients with chronic periodontitis.  J Periodontol 78: 498-503.
  39. Heitz-Mayfield LJ (2005) Disease progression: identification of high-risk groups and individuals for periodontitis.  J Clin Periodontol 32 Suppl 6: 196-209.
  40. Tomita S, Komiya-Ito A, Imamura K, Kita D, Ota K, et al. (2013) Prevalence of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia in Japanese patients with generalized chronic and aggressive periodontitis. Microbial Pathogenesis 61-62: 11-15.
  41. Funhoff  EG, Bollen M, Averill BA (2005) The Fe(III)Zn(II) form of recombinant human purple acid phosphatase is not activated by proteolysis.  J Inorg Biochem 99: 521-529.
Citation: Pushparani DS (2015) Low Serum Zinc and Increased Acid Phosphatase Activity in Type 2 Diabetes Mellitus with Periodontitis Subjects. Biochem Pharmacol (Los Angel) 4:162.

Copyright: © 2015 Pushparani DS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top